Search: id:"swepub:oai:DiVA.org:uu-342579" >
High doses of chole...
-
Westerberg, Per-Anton,1967-Uppsala universitet,Njurmedicin,County Hospital, Jönköping, Sweden
(author)
High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3-4 : results of a 12-week double-blind, randomized, controlled study
- Article/chapterEnglish2018
Publisher, publication year, extent ...
-
2017-05-30
-
Oxford University Press (OUP),2018
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-342579
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-342579URI
-
https://doi.org/10.1093/ndt/gfx059DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Background: Calcidiol insufficiency may accelerate the development of secondary hyperparathyroidism (SHPT). We tested the effect of a substantial increase in calcidiol on mineral metabolism in patients with chronic kidney disease (CKD).Methods: Ninety-five patients with CKD Stages 3-4, parathyroid hormone (PTH) above 6.8 pmol/L and calcidiol below 75 nmol/L were randomized to receive either cholecalciferol 8000 IU/day or placebo for 12 weeks. The primary endpoint was difference in the mean change in iPTH after 12 weeks. The proportion of participants having a 30% reduction in PTH and the effect on hand grip strength, fatigue and different biochemical variables were also investigated.Results: Baseline calcidiol was 57.5 ± 22 and 56.8 ± 22 nmol/L in the cholecalciferol and placebo groups, respectively. The corresponding concentrations of PTH were 10.9 ± 5 and 13.1 ± 9 pmol/L. Calcidiol increased to 162 ± 49 nmol/L in patients receiving cholecalciferol, and PTH levels remained constant at 10.5 ± 5 pmol/L. In the placebo group, calcidiol remained stable and PTH increased to 15.2 ± 11 pmol/L. The mean change in PTH differed significantly between the two groups (P < 0.01). The proportion of subjects reaching a 30% decrease in PTH did not differ. No effect on grip strength, fatigue, phosphate or fibroblast growth factor 23 was observed. Cholecalciferol treatment resulted in stable calcium concentrations and a substantial increase in calcitriol.Conclusion: Treatment with high daily doses of cholecalciferol in patients with CKD Stages 3-4 halts the progression of SHPT and does not cause hypercalcaemia or other side effects.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Sterner, Gunnar
(author)
-
Ljunggren, ÖstenUppsala universitet,Endokrinologi och mineralmetabolism(Swepub:uu)osteljun
(author)
-
Isaksson, Elin
(author)
-
Elvarson, FjölnirUppsala universitet,Institutionen för medicinska vetenskaper(Swepub:uu)fjoel918
(author)
-
Dezfoolian, Hamid
(author)
-
Linde, TorbjörnUppsala universitet,Njurmedicin(Swepub:uu)torblind
(author)
-
Uppsala universitetNjurmedicin
(creator_code:org_t)
Related titles
-
In:Nephrology, Dialysis and Transplantation: Oxford University Press (OUP)33:3, s. 466-4710931-05091460-2385
Internet link
Find in a library
To the university's database